Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Details Narrative)

v3.22.1
Cancer Genetics, Inc. Merger (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 30, 2021
Aug. 21, 2020
Mar. 31, 2022
Mar. 31, 2021
Mar. 30, 2022
Dec. 31, 2021
Feb. 23, 2021
Business Acquisition [Line Items]              
Common stock, par or stated value per share     $ 0.0001     $ 0.0001  
Business combination, acquisition related costs     $ 2,145      
Revenue percentage, description     Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments        
Common Stock [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues     406,000 805,000      
StemoniX [Member]              
Business Acquisition [Line Items]              
Assets acquired and liabilities assumed, current liabilities, accounts payable         $ 3,107    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 9,500    
StemoniX [Member] | Merger Agreement [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues 804,711            
Business combination consideration transferred $ 59,900            
StemoniX [Member] | Merger Agreement [Member] | Common Stock [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues 11,007,186            
Business combination, step acquisition, equity interest in acquiree, fair value $ 50,740            
StemoniX [Member] | Merger Agreement [Member] | Common Stock Warrants [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues 2,157,686            
Business combination, step acquisition, equity interest in acquiree, fair value $ 9,040            
StemoniX [Member] | Merger Agreement [Member] | Common Stock Options [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues 55,907            
Business combination, step acquisition, equity interest in acquiree, fair value $ 139            
StemoniX [Member] | Holders [Member] | Merger Agreement [Member]              
Business Acquisition [Line Items]              
Stock issued during period, shares, new issues   17,977,544          
Common stock, par or stated value per share   $ 0.0001          
Share-based payment award, shares purchased for award   891,780          
Share-based payment arrangement, option, exercise price range, lower range limit   $ 0.66          
Share-based payment arrangement, option, exercise price range, upper range limit   4.61          
Exercise price range, exercisable, weighted average exercise price   $ 1.46          
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]              
Business Acquisition [Line Items]              
Share-based payment award, shares purchased for award   143,890          
Shares issued, price per share   $ 5.9059 $ 5.9059       $ 5.9059
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member]              
Business Acquisition [Line Items]              
Business combination, acquisition related costs       $ 2,145      
Assets acquired and liabilities assumed, current liabilities, accounts payable       $ 63      
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Trade Names [Member]              
Business Acquisition [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 1,500        
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Customer Relationships [Member]              
Business Acquisition [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 8,000        
Royalty payment, percentage     1.00%